GPT and metabolic dysfunction-associated steatohepatitis: The highest dose (0.4 mg/day) led to NASH resolution without worsening of fibrosis in 59% of patients compared to 17% with placebo, along with significant reductions in steatosis scores, ALT (up to −60%), AST (up to −50%), GGT (up to −52%), HbA1c (up to 1.2% points) and body weight (up to −12.3 kg).